A number of studies have demonstrated the potential to detect MNA in serum and plasma from patients with NB at diagnosis across all tumour stages using PCR methodology (table 3), thus raising the prospect of using MYCN as a circulating biomarker [102–109]. This evidence concerns the gene MYCN and neuroblastoma.